3.2. Survival Analysis
DISEASE, METASTATIC DISEASE
In the front-line setting, median overall survival of 9.0 months (95% CI; 8.36-15.11) was reached, and 1- and 2-year survival rates reached values of 38.8 and 7.6, respectively, while the overall mPFS was 8.03 ± 0.99 (6.08-9.90) months.In patients with locally advanced disease, a global median OS of 16.36 months (95% CI; 14.35-18.38) was reached, and 1- and 2-year survival rates reached values of 72.2 and 29.2, respectively. In patients with metastatic disease, a global median OS of 6.23 months (95% CI; 4.32-8.13) was reached, and 1- and 2-year survival rates reached values of 18.1 and 3.0, respectively (
In patients with locally advanced disease, a median PFS of 9.6 months (95% CI; 4.91-14.20) was reached, and the PFS rate at one year was 39%. No patient achieved the 2-year PFS rate. In 20 patients with locally advanced disease who received 8 or more doses of nimotuzumab, the mOS increased to 17.4 months (IC95% 15.56-19.17), and 1- and 2-year survival rates reached values of 78.7 and 31.9, respectively (In patients with metastatic disease, a median PFS of 7.6 months was reached (95% CI; 6.08-9.90), and the PFS rates at one year and two years reached values of 20.5 and 5.1, respectively.